Company Overview and News

6
China is hitting reality now on `impossible’ tax, deficit goals

1h bworldonline
China’s government is grappling with an inconvenient truth: you can’t cut taxes, boost spending and reduce the budget deficit all at the same time.
NMR JBK GSC TFG CMAKY GSJ CGMBF GS GLSSP 8604 N33 NRSCF GJS

6
China Is Hitting Reality Now on `Impossible' Tax, Deficit Goals

1h theedgemarkets
(Sept 21): China’s government is grappling with an inconvenient truth: you can’t cut taxes, boost spending and reduce the budget deficit all at the same time.
NMR JBK GSC TFG CMAKY GSJ CGMBF GS GLSSP 8604 N33 NRSCF GJS

2
China's banks embrace Communist Party committees in risk crackdown

2018-06-27 theedgemarkets
BEIJING (June 27): China’s listed mid-tier and regional banks will face added pressure to curb risky activities following the formal establishment of Communist Party Committees at the lenders, bankers and analysts say.
CGMBF CICHY CHIB CMAKY CICHF CCB CKGOY 0939

2
China's banks embrace Communist Party committees in risk crackdown

2018-06-27 reuters
BEIJING (Reuters) - China’s listed mid-tier and regional banks will face added pressure to curb risky activities following the formal establishment of Communist Party Committees at the lenders, bankers and analysts say.
CGMBF CICHY CHIB CMAKY CICHF CCB CKGOY 0939

2
China's banks embrace Communist Party committees in risk crackdown

2018-06-27 malaymail
BEIJING, June 27 — China’s listed mid-tier and regional banks will face added pressure to curb risky activities following the formal establishment of Communist Party Committees at the lenders, bankers and analysts say.
CGMBF CICHY CHIB CMAKY CICHF CCB CKGOY 0939

15
China to unleash US$108 bil in reserves cut for most banks

2018-06-25 theedgemarkets
(June 25): China’s central bank will cut the amount of cash some lenders must hold as reserves, unlocking about 700 billion yuan (US$108 billion) of liquidity, as it seeks to control leverage and support smaller companies.
CGMBF SCGLF SCGLY GLE MS CMAKY

2
Anbang’s Long, Slow Road to Redemption - Bloomberg

2018-05-30 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
CGMBF 3968 2628 UBS LFC CMAKY ULSGF

 
China’s forex reserves are up – and so are fears of a US trade war hit

2018-04-08 scmp
China’s trade surplus has been the biggest contributor to its foreign exchange stockpile but that could change amid tensions with the United States
CGMBF CMAKY

4
A $31 Billion Trading Halt Has Left HNA Investors Trapped - Bloomberg

2018-03-13 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
CGMBF CHCJY CHBJF CMAKY MSCI

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...